undamentalytics Newsletter
Sign in

Glaukos Corp revenue

Glaukos Corp's revenue was $507m in fiscal 2025, up 32.3% on the year before. Since fiscal 2013 ($20.9m) it has grown at a compound 30.4% a year. Over the last twelve months it was $690m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue214672114159181237225294283315383507690
Growth on the year before—+117.6%+57.3%+59.5%+39.2%+13.8%+30.7%−5.1%+30.7%−3.8%+11.3%+21.9%+32.3%—
Gross profit18345998138156198133227214239289283447
Gross margin87.9%75.0%81.9%85.9%86.8%86.2%83.7%59.2%77.3%75.6%76.0%75.5%55.7%64.8%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Glaucoma $421M 83.0% ▲ 38.8%
Corneal Health $86.4M 17.0% ▲ 7.7%
Geography
Region Revenue Share YoY
United States $375M 73.9% ▲ 38.9%
Outside the US $132M 26.1% ▲ 16.8%

From Glaukos Corp's 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Health Care Equipment: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Glaukos Corp $690m 46.9% 31.5%
Transmedics Group, Inc. $668m 25.8% 64.2%
Novocure Ltd $725m 12.9% 12.9%
Myriad Genetics Inc $807m -3.2% 4.9%
Bioventus Inc. $586m 3.9% 5.2%
Irhythm Holdings, Inc. $825m 25.6% 22.2%

Compare with peers

Head to head: GKOS vs TMDXGKOS vs NVCRGKOS vs MYGNBVS vs GKOS

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Glaukos Corp's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Glaukos Corp.